[8-K] Salarius Pharmaceuticals, Inc. Reports Material Event

Salarius Pharmaceuticals, Inc. clarifies that its common stock remains listed and trading on the Nasdaq Capital Market under the ticker “SLRX”.

Rhea-AI Filing Summary

Salarius Pharmaceuticals, Inc. clarifies that its common stock remains listed and trading on the Nasdaq Capital Market under the ticker “SLRX”. The company became aware that certain financial data platforms, including Yahoo Finance and CapIQ, incorrectly reported that it had been delisted effective November 13, 2025, and has contacted them to correct this error.

The company notes that it regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price rule, as of a letter dated September 4, 2025, and later regained compliance with Nasdaq Listing Rule 5550(b)(1), the equity standard, as of an October 10, 2025 letter. Salarius also highlights that, following completion of its strategic merger with Decoy Therapeutics, Inc. on November 13, 2025, it continues to meet the continued listing requirements and has not received any non-compliance notice from Nasdaq.

Insights

Equity markets and listing standards analyst

Salarius corrects false delisting reports and confirms ongoing Nasdaq compliance.

Salarius Pharmaceuticals, Inc. reports that some market data platforms, including Yahoo Finance and CapIQ, wrongly showed the company as delisted from the Nasdaq Capital Market effective November 13, 2025. The company states that its common stock continues to trade on Nasdaq under the symbol SLRX and that it has reached out to those platforms to correct the data.

The company emphasizes its recent compliance progress with Nasdaq standards. It received a September 4, 2025 letter confirming compliance with Listing Rule 5550(a)(2), which covers the minimum bid price, and an October 10, 2025 letter confirming compliance with Listing Rule 5550(b)(1), the equity standard. It also notes that after completing its strategic merger with Decoy Therapeutics, Inc. on November 13, 2025, it remains listed on Nasdaq and has not received any notice of non-compliance, suggesting that the false delisting entries stem from third-party data errors rather than exchange action.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/17/2025 - 05:23 PM Learn about SEC filing dates

0001615219FALSE2450 Holcombe Blvd.Suite XHoustonTX00016152192025-08-152025-08-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2025

SALARIUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware

001-36812

46-5087339

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification Number)

2450 Holcombe Blvd. Suite X Houston, TX

77021

(Address of principal executive offices)

(Zip Code)

(713) 913-5608
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class						Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001						SLRX			The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Item 7.01 Regulation FD

On November 17, 2025, Salarius Pharmaceuticals, Inc. (the “Company”) became aware that certain financial market data platforms, including Yahoo Finance and CapIQ, published information stating that the Company had been delisted from the Nasdaq Capital Market effective November 13, 2025. This information is inaccurate. The Company’s common stock continues to be listed and traded on the Nasdaq Capital Market under the ticker symbol “SLRX”. The Company has contacted these platforms to correct this inaccurate information.

As previously disclosed, on September 4, 2025, the Company received a letter from the Nasdaq Hearings Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Subsequently, on October 10, 2025, the Company received a letter from the Hearings Panel notifying the Company that it had regained compliance with Nasdaq Listing Rule 5550(b)(1) (the “Equity Standard”). On November 13, 2025, the Company announced that it had completed its strategic merger transaction with Decoy Therapeutics, Inc. Following consummation of the merger, the Company continues to be listed and traded on the Nasdaq Capital Market under the ticker symbol “SLRX.” The Company has not received any notification from Nasdaq indicating that it is not compliant with the continued listing requirements of the Nasdaq Capital Market.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SALARIUS PHARMACEUTICALS, INC.

Date: November 17, 2025

By:

/s/ Mark J. Rosenblum

Mark J. Rosenblum Executive Vice President & Chief Financial Officer